{"id":642249,"date":"2023-03-13T16:50:01","date_gmt":"2023-03-13T16:50:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=642249"},"modified":"2023-03-13T16:50:01","modified_gmt":"2023-03-13T16:50:01","slug":"car-tcell-therapy-pipeline-constitutes-193-key-companies-continuously-working-towards-developing-450-car-tcell-therapy-treatment-therapies-analyzes-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/car-tcell-therapy-pipeline-constitutes-193-key-companies-continuously-working-towards-developing-450-car-tcell-therapy-treatment-therapies-analyzes-delveinsight_642249.html","title":{"rendered":"CAR T-Cell Therapy pipeline constitutes 193+ key companies continuously working towards developing 450+ CAR T-Cell Therapy treatment therapies, analyzes DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1678698522.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"CAR T-Cell Therapy pipeline constitutes 193+ key companies continuously working towards developing 450+ CAR T-Cell Therapy treatment therapies, analyzes DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1678698522.jpeg\" alt=\"CAR T-Cell Therapy pipeline constitutes 193+ key companies continuously working towards developing 450+ CAR T-Cell Therapy treatment therapies, analyzes DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>CAR T-Cell Therapy pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsights,<strong>&nbsp;&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cart-cell-therapy-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">CAR T-Cell Therapy Competitive landscape, 2023<\/a>&rdquo;<\/strong>&nbsp;report provides comprehensive insights about 193+ companies and CAR T &ndash; Cell Therapy drugs in CAR T &ndash; Cell Therapy Competitive landscape. It covers the therapeutics assessment by product type,stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">A type of treatment in which a patient&rsquo;s T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient&rsquo;s blood. Then the gene for a special receptor that binds to a certain protein on the patient&rsquo;s cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. CAR T-cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer. Also called chimeric antigen receptor T-cell therapy.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about the CAR T-Cell Therapy pipeline analysis report, click here:&nbsp;<\/strong><em><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cart-cell-therapy-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">CAR T-Cell Therapy Competitive landscape<\/a><\/strong><\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the CAR T &ndash; Cell Therapy Competitive landscape report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Leading CAR T &ndash; Cell Therapy Companies working in the market are Alnylam Pharmaceuticals, JW Therapeutics, Gilead Sciences, Janssen Pharmaceuticals, Innovent Biologics, Sorrento Therapeutics, Cartesian Therapeutics, Novartis, Poseida Therapeutics, Tessa Therapeutics, Miltenyi Biomedicine, Bristol-Myers Squibb, Autolus Limited, Carsgen Therapeutics, Cellular Biomedicine Group, Eureka Therapeutics, Formula Pharmaceuticals, Mustang Bio, MolMed and Others.<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>Key CAR T &ndash; Cell Therapy therapies in various stages of development include JWCAR029, JCAR017, CT 103A, MB-CART2019.1, Kymriah, KTE-X19, P-BCMA-101, Descartes-11, Orvacabtagene autoleucel, BPX-603 and Others.<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>In May 2022, Novartis announced the US Food and Drug Administration has granted accelerated approval for Kymriah (tisagenlecleucel ) for the treatment of adult patients with relapsed or refractory (r\/r) follicular lymphoma (FL) after two or more lines of systemic therapy.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s CAR T &ndash; Cell Therapy Report covers around 450+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Assessment by CAR T &ndash; Cell Therapy Product Type<\/li>\n<li>Assessment by Stage and Product Type of CAR T &ndash; Cell Therapy<\/li>\n<li>Assessment by Route of Administration<\/li>\n<li>Assessment by Stage and Route of Administration of CAR T &ndash; Cell Therapy<\/li>\n<li>Assessment by CAR T &ndash; Cell Therapy Molecule Type<\/li>\n<li>Assessment by Stage and Molecule Type of CAR T &ndash; Cell Therapy<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Emerging CAR T &ndash; Cell Therapy Drugs Under Different Phases of Clinical Development Include:<\/strong><\/p>\n<p style=\"text-align: justify;\">Some of the CAR T &ndash; Cell Therapy therapies are Kymriah, BPX-603 and Many Others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Further CAR T &ndash; Cell Therapy product details are provided in the report. Download the CAR T &ndash; Cell Therapy Pipeline report to learn more about the emerging CAR T-Cell therapies at:&nbsp;<\/strong><em><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cart-cell-therapy-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/cart-cell-therapy-competitive-landscape<\/a><\/strong><\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key companies in the CAR T &ndash; Cell Therapy Therapeutics Market:<\/strong><\/p>\n<p style=\"text-align: justify;\">Some of the CAR T &ndash; Cell Therapy Companies working in the market are Alnylam Pharmaceuticals, JW Therapeutics, Gilead Sciences, Janssen Pharmaceuticals, Innovent Biologics, Sorrento Therapeutics, Cartesian Therapeutics, Novartis, Poseida Therapeutics, Tessa Therapeutics, Miltenyi Biomedicine, Bristol-Myers Squibb, Autolus Limited, Carsgen Therapeutics, Cellular Biomedicine Group, Eureka Therapeutics, Formula Pharmaceuticals, Mustang Bio, MolMed and Others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report to know in detail about the recent developments&nbsp; and advancements in CAR T &ndash; Cell Therapy clinical trials &ndash;&nbsp;<\/strong><em><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cart-cell-therapy-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Phases of CAR T &ndash; Cell Therapy Drugs in Pipeline<\/a><\/strong><\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\">1. CAR T &ndash; Cell Therapy Pipeline Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. CAR T &ndash; Cell Therapy Pipeline Report Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. CAR T &ndash; Cell Therapy Pipeline: Overview<\/p>\n<p style=\"text-align: justify;\">4. Analytical Perspective In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">5. CAR T &ndash; Cell Therapy Clinical Trial Therapeutics<\/p>\n<p style=\"text-align: justify;\">6. CAR T &ndash; Cell Therapy Pipeline: Late Stage Products (Pre-registration)<\/p>\n<p style=\"text-align: justify;\">7. CAR T &ndash; Cell Therapy Pipeline: Late Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">8. CAR T &ndash; Cell Therapy Pipeline: Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">9. CAR T &ndash; Cell Therapy Pipeline: Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">10.&nbsp; CAR T &ndash; Cell Therapy Pipeline Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">11. Inactive Products in the CAR T &ndash; Cell Therapy Pipeline<\/p>\n<p style=\"text-align: justify;\">12. Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">13. Key CAR T &ndash; Cell Therapy Companies<\/p>\n<p style=\"text-align: justify;\">14. Key Products in the CAR T &ndash; Cell Therapy Pipeline<\/p>\n<p style=\"text-align: justify;\">15. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">16. CAR T &ndash; Cell Therapy Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">17. Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">18. Analyst Views<\/p>\n<p style=\"text-align: justify;\">19. Appendix<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample PDF Report to know more about @&nbsp;<\/strong><em><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cart-cell-therapy-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">CAR T-Cell Drugs and Medication<\/a><\/strong><\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=car-tcell-therapy-pipeline-constitutes-193-key-companies-continuously-working-towards-developing-450-car-tcell-therapy-treatment-therapies-analyzes-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=car-tcell-therapy-pipeline-constitutes-193-key-companies-continuously-working-towards-developing-450-car-tcell-therapy-treatment-therapies-analyzes-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CAR T-Cell Therapy pipeline DelveInsights,&nbsp;&ldquo;CAR T-Cell Therapy Competitive landscape, 2023&rdquo;&nbsp;report provides comprehensive insights about 193+ companies and CAR T &ndash; Cell Therapy drugs in CAR T &ndash; Cell Therapy Competitive landscape. It covers the therapeutics assessment by product type,stage, route &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/car-tcell-therapy-pipeline-constitutes-193-key-companies-continuously-working-towards-developing-450-car-tcell-therapy-treatment-therapies-analyzes-delveinsight_642249.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,413],"tags":[],"class_list":["post-642249","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/642249","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=642249"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/642249\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=642249"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=642249"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=642249"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}